 Painless electrolyte solutions |
| What is claimed is: 1. A composition consisting of: (a) electrolytes selected from the group ... |
|
| Method for enhancing healing of corneal endothelial wounds |
| Method using a non-steroidal antiinflammatory compound, such as indomethacin, and/or a growth ... |
|
| Method and agents for promoting wound healing |
| In accordance with the present invention, diagnostic and therapeutic protocols are proposed that ... |
|
| Control of post-surgical intraocular pressure using clonidine derivatives |
| OF THE INVENTION The present invention utilizes certain clonidine derivatives, as defined above, ... |
|
| Tissue irrigating solution |
| OF THE PREFERRED EMBODIMENTS The present invention is directed generally to an improved technique ... |
|
| Indolyl substituted hydroxylamine derivatives |
| OF THE INVENTION More particularly the invention relates to the compounds of formula I ##STR2## ... |
|
| Prevention of synovial adhesions |
| OF THE INVENTION A wide variety of lipid particles may include a nonsteroidal antiinflammatory ... |
|
| Method for reducing unwanted cellular adhesions |
| In accordance with one aspect of the present invention there is provided a method for reducing ... |
|
| Anti-infective and anti-inflammatory releasing systems for medical devices |
| Devices are provided having a polymer coating incorporating compounds inhibiting inflammation and ... |
|
|
Synthetic peptide inhibitors of HIV transmission
| Details |
Inventors: Bolognesi, Dani P.; Matthews, Thomas J.; Wild, Carl T.;
Assignee: Duke University (Durham, NC)
Primary Examiner: Nucker; Christine M.
Assistant Examiner: Stucker; Jeffrey
Attorney, Agent or Firm: Pennie & Edmonds
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptides corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells. |
|
DETAILED DESCRIPTION OF THE INVENTION 5.
1 DP-178 AND DP-178-LIKE PEPTIDES 5.
2 ASSAYS FOR ANTIVIRAL ACTIVITY 5.
3 USES OF THE PEPTIDES OF THE INVENTION 6.
EXAMPLE: DP-178 (SEQ ID:1) IS A POTENT INHIBITOR OF HIV-1 INFECTION 6.
1 MATERIALS AND METHODS 6.
1.
1.
Peptide Synthesis 6.
1.
2.
Virus 6.
1.
3.
Cell Fusion Assay 6.
1.
5.
Reverse Transcriptase Assay 6.
2 RESULTS 6.
2.
1.
Peptide Inhibition of Infected Cell-Induced Syncytia Formation 6.
2.
2.
Peptide Inhibition of Infection by Cell-Free Virus 1.
INTRODUCTION The present invention relates to DP-178 (SEQ ID:1), a peptide corresponding to amino acids 638 to 673 of the HIV-1.
sub.
LAI transmembrane protein (TM) gp41, and portions, analogs, and homologs of DP-178 (SEQ ID:1), all of which exhibit anti-retroviral activity.
Such anti-retroviral activity includes, but is not limited to, the inhibition of HIV transmission to uninfected CD-4.
sup.
+ cells.
Further, the invention relates to the use of DP-178 (SEQ ID:1) and DP-178 fragments and/or analogs or homologs as inhibitors of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Still further, the invention relates to the use of DP-178 as a HIV subtype-specific diagnostic.
The invention is demonstrated by way of a working example wherein DP-178 (SEQ ID:1), and a peptide whose sequence is homologous to DP-178 are each shown to be potent, non-cytotoxic inhibitors of HIV-1 transfer to uninfected CD-4.
sup.
+ cells.
2.
BACKGROUND OF THE INVENTION 2.
1 THE HUMAN IMMUNODEFICIENCY VIRUS The human immunodeficiency virus (HIV) has been implicated as the primary cause of the slowly degenerative immune system disease termed acquired immune deficiency syndrome (AIDS) (Barre-Sinoussi, F.
et al.
, 1983, Science 220:868-870; Gallo, R.
et al.
, 1984, Science 224:500-503).
there are at least two distinct types of HIV: HIV-1 (Barre-Sinoussi, F.
et al.
, 1983, Science 220:868-870; Gallo R.
et al.
, 1984, Science 224:500-503) and HIV-2 (Clavel, F.
et al.
, 1986, Science 233:343-346; Guyader, M.
et al.
, 1987, Nature 326:662-669)
|
| Related patents |
|
|
Compounds which inhibit HIV replication
A first aspect of the present invention is a peptide selected from the group consisting of: (a) the peptide DP-107, which has the formula, from amino terminus to carboxy ...
|
|
|
Hybrid polypeptides with enhanced pharmacokinetic properties
OF THE INVENTION Described herein are peptide sequences, referred to as enhancer peptide sequences, derived from various retroviral envelope (gp41) protein sequences ...
|
|
|
1-aryl-2-hydroxyethyl amides as potassium channel openers
OF THE INVENTION The present invention provides novel aryl hydroxyethyl amides and related derivatives which are modulators of the KCNQ potassium channels and which ...
|
|
|
Method of eliciting anti-HIV-1 helper T cell responses
A number of HIV-1 p24 peptides that elicit HIV-1-specific helper T cell responses have been identified. Contemplated within the scope of this invention are methods of ...
|
|
|
pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof
OF THE INVENTION Before the present methods and treatment methodology are described, it is to be understood that this invention is not limited to particular methods, ...
|
|
|
GPIb.alpha. fragments and recombinant DNA expression vectors
As set forth in aforementioned application Ser. No. 07/470,674, there are provided peptides comprising any peptide of the 45 kDa amino terminal tryptic fragment of ...
|
|
|
Expression vector encoding hybrid immunoglobulins
Ligand binding partners as defined herein are proteins known to function to bind specifically to target ligand molecules, and are generally found in their native state ...
|
|
|
Hybrid immunoglobulins
Ligand binding partners as defined herein are proteins known to function to bind specifically to target ligand molecules, and are generally found in their native state ...
|
|
|
GPIb-lipid complex and uses thereof
What is claimed is: 1. A complex comprising a lipid and a conjugate of GPIb or a GPIB fragment having a von Willebrand factor-binding capability that is almost at the ...
|
|
|
Immuno-modulating antitumor activities of Ganoderma lucidum (Reishi) polysaccharides
We claim: 1. A composition comprising one or more fractions, the one or more fractions obtainable by a process comprising: homogenizing tissue of Ganoderma lucidum; ...
|
|
|
Drugs 
